Boston Scientific Lowers 2026 Profit Forecast, Narrows Revenue Growth Outlook

Boston Scientific has revised its 2026 profit forecast downward while also narrowing its revenue growth expectations. In an update shared with investors, the company lowered its adjusted earnings per share guidance for 2026 to a range of $2.10-$2.20, down from the previous estimate of $2.20-$2.30. On the revenue side, Boston Scientific now projects annual organic revenue growth of 6%-8% for 2026, below the previously stated range of 7%-9%. The company cited foreign exchange fluctuations and competitive pressures in certain markets as key reasons for the revision. Analysts note that despite Boston Scientific's efforts to protect profit margins, rising R&D expenses and regulatory costs are increasing financial burdens. The company is particularly focused on new product launches in the cardiovascular devices segment. These updated 2026 forecasts from Boston Scientific came in slightly below market expectations. The company's shares experienced a modest decline in pre-market trading following the news. Investors are closely watching how the company will balance cost control and growth strategies in the coming period. This is not investment advice.